Idorsia: latest news - GoINPHARMA
Tuesday, 22 January 2019 - 3:27

Idorsia

Switzerland is the cradle of European biotech industry

The Swiss economic-financial daily Finanz und Wirstschaft yesterday published a detailed analysis of the Swiss biotech industry. Switzerland is undoubtedly the European biotech hub, housing as many as 237 biotech companies, 14 of which listed on the stocks market. Investors…

Biotech Idorsia’s results meet expectations

Switzerland-based biotech Idorsia today has announced its Q2 2018 results. The company was established only one year ago after JnJ had acquired Actelion ($30bn), providing its founder  Jean-Paul Clozel the capital to create a new company. The results have reportedly…

Jean-Paul Clozel describes “unicorn” Idorsia’s strategy

Jean-Paul Clozel (62), head of Switzerland-based biotech Idorsia, has been elected Manager of the year by the readers of the Swiss economic and financial weekly Finanz und Wirtschaft, which has published today a long interview to the French manager. Clozel,…

Excellent momentum of Idorsia continues, shares rise

The Swiss biotech Idorsia keeps surprising analysts and investors with excellent financial performances and strategic decisions. Its shares have increased by over 34% over the last three months, taking its capitalization to CHF2.76bn. Moreover, Idorsia before Christmas entered into a…

JnJ secures rights to Idorsia’s hypertension therapy ($160m)

Switzerland-based biotech group Idorsia, established as JnJ acquired Actelion, has announced that Janssen–a subsidiary of JnJ’s–has exercised its right to co-develop the investigational drug aprocitentan (ACT-132577). Aprocitentan is an investigational hypertension therapy already tested in a Phase II clinical trial….

Idorsia born from Actelion: a dramatic +37% on first trading day

New pharmaceutical group Idorsia was created yesterday from the acquisition of Actelion by US-based Johnson & Johnson. The new spin-off debuted yesterday in Zurich at the initial price of CHF10, and closed its first day at CHF13.65, totaling a market…